Market Place
Sourcing Support
Glaukos Announces Participation in Upcoming Investor Conferences
08 Nov 2024 //
BUSINESSWIRE
Glaukos Announces Third Quarter 2024 Financial Results
04 Nov 2024 //
BUSINESSWIRE
Glaukos Achieves Positive Outcomes In Phase 3 Trial For Epioxa™
16 Oct 2024 //
BUSINESSWIRE
Ripple Therapeutics Announces Evaluation and Licensing Agreements with Glaukos
15 Oct 2024 //
ACCESSWIRE
Glaukos To Present Abstracts At 2024 AAO Annual Meeting
14 Oct 2024 //
BUSINESSWIRE
Glaukos To Release Q3 2024 Results after Market Close November 4
09 Oct 2024 //
BUSINESSWIRE
Glaukos Announces Participation in Upcoming Investor Conferences
16 Aug 2024 //
BUSINESSWIRE
Glaukos Announces Second Quarter 2024 Financial Results
31 Jul 2024 //
BUSINESSWIRE
Glaukos To Release Q2 2024 Results On July 31
10 Jul 2024 //
BUSINESSWIRE
Glaukos Exchanges $230M Convertible Notes For Common Stock
14 Jun 2024 //
BUSINESSWIRE
Glaukos Announces Participation in Upcoming Investor Conferences
28 May 2024 //
BUSINESSWIRE
Glaukos Announces First Quarter 2024 Financial Results
01 May 2024 //
BUSINESSWIRE
Glaukos Announces the Release of its 2023 Sustainability Report
16 Apr 2024 //
BUSINESSWIRE
Glaukos to Release Q1 2024 Financial Results
10 Apr 2024 //
BUSINESSWIRE
Glaukos Receives Permanent J-code for iDose TR (travoprost intracameral implant)
03 Apr 2024 //
BUSINESSWIRE
Glaukos To Present Numerous Scientific Abstracts at the Meeting
01 Apr 2024 //
BUSINESSWIRE
Glaukos Announces Fourth Quarter and Full Year 2023 Financial Results
21 Feb 2024 //
BUSINESSWIRE
Glaukos to Release Fourth Quarter and Full Year 2023 Financial Results
31 Jan 2024 //
BUSINESSWIRE
Glaukos Announces Unaudited Fourth Quarter and Full Year 2023 Net Sales
09 Jan 2024 //
BUSINESSWIRE
Glaukos Announces Participation in the J.P. Morgan Healthcare Conference
20 Dec 2023 //
BUSINESSWIRE
Glaukos Announces FDA Approval of iDose® TR (travoprost intracameral implant)
14 Dec 2023 //
BUSINESSWIRE
Glaukos Announces Participation in Stifel Healthcare Conference
07 Nov 2023 //
BUSINESSWIRE
Glaukos Announces Third Quarter 2023 Financial Results
01 Nov 2023 //
BUSINESSWIRE
Glaukos Technologies Featured in Numerous Scientific Abstracts
31 Oct 2023 //
BUSINESSWIRE
Stuart Therapeutics Announces Exclusive Worldwide License Agreement with Glaukos
18 Oct 2023 //
PR NEWSWIRE
Glaukos to Release Third Quarter 2023 Financial Results
11 Oct 2023 //
BUSINESSWIRE
Glaukos Announces Participation in Wells Fargo Healthcare Conference
23 Aug 2023 //
BUSINESSWIRE
Glaukos Announces Second Quarter 2023 Financial Results
02 Aug 2023 //
BUSINESSWIRE
Glaukos Enters into a Collaboration and Marketing Agreement with Radius XR, Inc.
17 Jul 2023 //
BUSINESSWIRE
Glaukos to Release Second Quarter 2023 Financial Results
12 Jul 2023 //
BUSINESSWIRE
Glaukos Achieves Pipeline Milestone with Enrollment Completion for Epioxa
05 Jun 2023 //
BUSINESSWIRE
Glaukos Announces Participation in the William Blair Growth Stock Conference
24 May 2023 //
BUSINESSWIRE
Glaukos Announces FDA Acceptance of NDA Submission for iDose TR
05 May 2023 //
BUSINESSWIRE
Glaukos to Release Q1 2023 Financial Results after Market Close on May 3
12 Apr 2023 //
BUSINESSWIRE
Celanese Announces Agreement with Glaukos for Release Glaucoma Treatment
05 Apr 2023 //
BUSINESSWIRE
Glaukos Submits New Drug Application to U.S. FDA for iDose TR
27 Feb 2023 //
BUSINESSWIRE
Glaukos Announces Fourth Quarter and Full Year 2022 Financial Results
22 Feb 2023 //
BUSINESSWIRE
Glaukos Announces Participation in the Citi Healthcare Conference
15 Feb 2023 //
BUSINESSWIRE
Glaukos to Release Fourth Quarter and Full Year 2022 Financial Results
01 Feb 2023 //
BUSINESSWIRE
Glaukos Announces Positive Results for iDose TR Exchange Trial
10 Jan 2023 //
BUSINESSWIRE
Glaukos Announces Positive Updates for Corneal Health Pipeline Programs
10 Jan 2023 //
BUSINESSWIRE
Glaukos Announces Participation in the J.P. Morgan Healthcare Conference
29 Dec 2022 //
BUSINESSWIRE
Glaukos Announces Participation in the Stephens Annual Investment Conference
07 Nov 2022 //
BUSINESSWIRE
Glaukos to Release Q3 2022 Financial Results after Market Close on November 2
12 Oct 2022 //
BUSINESSWIRE
Glaukos Featured in Numerous Scientific Abstracts at Annual Meeting
28 Sep 2022 //
BUSINESSWIRE
Glaukos beats path to FDA after eye implant trials hit goals
14 Sep 2022 //
FIERCEPHARMA
Ionis, AZ going to FDA with PhIII data in hand; Glaukos touts double PhIII win
08 Sep 2022 //
ENDPTS
Glaukos Announces Positive Outcomes for Both Phase 3 Pivotal Trials of iDose TR
07 Sep 2022 //
BUSINESSWIRE
Glaukos Announces More Than 1 Million iStent Technologies Implanted Worldwide
06 Sep 2022 //
BUSINESSWIRE
Burns & Levinson Represents iVeena in Licensing Agreement with Glaukos Corp
29 Aug 2022 //
PRNEWSWIRE
Glaukos Licenses Iveena’s Investigational Keratoconus Therapy
24 Aug 2022 //
BUSINESSWIRE
Glaukos Announces Participation in the Wells Fargo Healthcare Conference
24 Aug 2022 //
BUSINESSWIRE
Glaukos nets FDA OK for pressure-relieving glaucoma eye stent
04 Aug 2022 //
FIERCEBIOTECH
Glaukos Corporation Announces Second Quarter 2022 Financial Results
03 Aug 2022 //
BUSINESSWIRE
Glaukos to Release Q2 2022 Financial Results after Market Close on August 3
13 Jul 2022 //
BUSINESSWIRE
Glaukos Announces Participation in the William Blair Growth Stock Conference
02 Jun 2022 //
BUSINESSWIRE
Glaukos Announces the Release of its 2021 Sustainability Report
20 Apr 2022 //
BUSINESSWIRE
Glaukos to Release Q1 2022 Financial Results after Market Close on May 4
13 Apr 2022 //
BUSINESSWIRE
Glaukos Commences Phase 2 Corneal Health Clinical Program for iLink Therapy
14 Mar 2022 //
BUSINESSWIRE
Glaukos Corporation Announces Q4 and Full Year 2021 Financial Results
22 Feb 2022 //
BUSINESSWIRE
